查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1513367

全球放射性藥物市場：按最終用戶、放射性同位素、應用、類型：機會分析和產業預測（2024-2033）

Radiopharmaceuticals Market By End User, By Radioisotope, By Application, By Type : Global Opportunity Analysis and Industry Forecast, 2024-2033
出版日期: | 出版商: Allied Market Research | 英文 500 Pages | 商品交期: 2-3個工作天內

價格
2023年全球放射性藥物市場規模預計為79億美元，預計2033年將達218億美元，2024年至2033年複合年成長率為10.6%。放射性藥物是含有放射性化學元素（稱為放射性同位素）的藥物。根據輻射類型，放射性同位素用於診斷和治療各種疾病。其用途範圍從測試和治療大腦、心臟、腎臟和骨骼等各種器官到治療癌症和甲狀腺功能亢進。放射性藥物透過注射或口服給予患者，並可使用外部醫療設備和測試進行監測和分析。大多數國家都制定了專門的安全措施，以保護患者和醫護人員免受這些藥物的潛在不良影響。
放射性藥物市場-IMG1
放射性藥物市場主要由慢性病的增加、技術進步以及診斷和治療過程中應用的擴大所推動。隨著癌症、心血管疾病和神經系統疾病等慢性病的盛行率持續上升，對有效診斷工具和標靶治療的需求不斷成長。放射性藥物可以提供精確的影像和治療方案，擴大被認為是對抗這些疾病的寶貴工具。此外，PET和SPECT等診斷影像技術的進步顯著提高了診斷準確性和效率，可以更早檢測和更好地管理疾病，這也推動了市場成長。此外，個人化醫療方法的出現正在推動對放射性藥物的需求，因為它們可以根據個別患者的特徵和分子標靶進行客製化治療。然而，開發和生產放射性藥物的成本很高，阻礙了市場的成長。這包括與研究、臨床試驗、製造流程和監管合規相關的成本。此外，放射性藥物的複雜性需要專門的基礎設施和專業知識，進一步增加了財務負擔。相較之下，放射性藥物研發活動正在考慮用於治療診斷學等領域，將診斷影像與標靶治療相結合，為市場成長提供了機會。放射性藥物市場按類型、應用、放射性同位素、最終用戶和地區進行細分。按類型分類，市場分為診斷市場和治療市場。根據應用，它們分為癌症、循環系統和其他。癌症領域又分為攝護腺癌、乳癌、胃腸癌、肺癌、腦腫瘤等。其他部分進一步分為神經學應用和其他應用。在放射性同位素的基礎上，市場分為碘I、鎵-68、Technetium-99m、氟-18、銅-64、鍶-89、釔-90、鐳-223、錒-225、鎦-177、銅-67，鋱-161，鋯-89，其他就完成了。依最終用戶分類，市場分為醫院/診所、醫學影像中心等。按地區分類，包括北美（美國、加拿大）、歐洲（德國、英國、西班牙、義大利其他歐洲國家）、亞太地區（印度、中國、澳洲、日本、韓國、泰國、馬來西亞、印尼、新加坡和台灣） 、中國和亞太其他地區）以及拉丁美洲、中東和非洲（巴西、拉丁美洲其他地區、中東和非洲）。全球放射性藥物市場的主要企業包括拜耳公司、康德樂、禮來公司、Bracco、Isotopia Molecular Imaging Ltd.、Actinium Pharmaceuticals, Inc.、諾華公司、Curium Pharma、Nippon Mediphysicals Co., Ltd.、Jubilant Pharmics Co. Ltd、Jubilant Pharmova Limited、Eckert & Ziegler、NorthStar Radioisotopes、國家原子能公司ROSATOM、SOFIE、Lantheus、Telix Pharmaceuticals Limited、Clarity Pharmaceuticals、Fusion Pharmaceuticals Inc.、PRECIRIX、ITM Isotope Technologies Munceuticals、Fusion Pharmaceuticals Inc.、PRECIRIX、ITM Isotope Technologies Munich SE . Necsa) 和Eczacibasi。市場上營運的主要公司正在尋求協議、收購、擴張、臨床試驗、產品核可、產品升級、合約、產品開發、聯盟、地理擴張和合資企業作為擴大產品系列。

相關人員的主要利益

  • 本報告定量分析了 2023 年至 2033 年放射性藥物市場分析的細分市場、當前趨勢、估計趨勢和動態，並確定了一般放射性藥物市場的機會。
  • 我們提供市場研究以及與市場促進因素、市場限制和市場機會相關的資訊。
  • 波特的五力分析強調買家和供應商幫助相關人員做出利潤驅動的商業決策並加強供應商-買家網路的力量。
  • 對放射性藥物市場細分的詳細分析有助於識別市場機會。
  • 我們根據每個地區的主要國家對全球市場的收益貢獻繪製了地圖。
  • 市場公司定位有助於基準化分析並提供對市場公司當前地位的清晰了解。
  • 該報告包括對區域和全球放射性藥物市場趨勢、主要企業、細分市場、應用領域和市場成長策略的分析。

目錄

第1章簡介

第 2 章執行摘要

第3章市場概況

  • 市場定義和範圍
  • 主要發現
    • 影響因素
    • 主要投資機會
  • 波特五力分析
  • 市場動態
    • 促進因素
      • 慢性病增加
      • 主要企業更多採用策略
      • 增加研發活動
    • 抑制因素
      • 開發引進放射性藥物的成本高昂
    • 機會
      • 研發線產品增加

第4章放射性藥物市場：依最終使用者分類

  • 概述
  • 醫院/診所
  • 醫學影像中心
  • 其他

第5章放射性藥物市場：依放射性同位素分類

  • 概述
  • Technetium99m
  • 鎵68
  • 碘I
  • 氟18
  • 銅64
  • 鍶89
  • 釔90
  • 鐳223
  • 錒225
  • 鎦177
  • 銅67
  • 鋱161
  • 鋯89
  • 其他

第6章 放射性藥物市場：依應用分類

  • 概述
  • 癌症
    • 癌症放射性藥物市場：依類型
  • 循環系統
  • 其他
    • 其他放射性藥物市場：依類型

第7章放射性藥物市場：依類型

  • 概述
  • 診斷
  • 治療性的

第8章放射性藥物市場：按地區

  • 概述
  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 其他
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
    • 馬來西亞
    • 印尼
    • 新加坡
    • 台灣
    • 其他
  • 拉丁美洲/中東/非洲
    • 巴西
    • 其他

第9章 競爭格局

  • 介紹
  • 關鍵成功策略
  • 10家主要企業產品圖譜
  • 競爭對手儀表板
  • 競爭熱圖
  • 主要企業定位（2023年）

第10章 公司簡介

  • Bayer AG
  • Cardinal Health
  • Curium Pharma
  • Eli Lilly and Company
  • Jubilant Pharmova Limited
  • Lantheus
  • ITM Isotope Technologies Munich SE
  • Telix Pharmaceuticals Limited
  • Eckert & Ziegler
  • Bracco
  • South African Nuclear Energy Corporation（NECSA）
  • NorthStar Medical Radioisotopes
  • The State Atomic Energy Corporation ROSATOM
  • SOFIE
  • Isotopia Molecular Imaging
  • Fusion Pharmaceuticals Inc.
  • Clarity Pharmaceuticals
  • Actinium Pharmaceuticals, Inc.
  • PRECIRIX
  • Novartis AG
  • Nihon Medi-Physics Co. Ltd
  • GE Healthcare
  • Eczacibasi
Product Code: A14458
The radiopharmaceuticals market was valued at $7.9 billion in 2023 and is estimated to reach $21.8 billion by 2033, exhibiting a CAGR of 10.6% from 2024 to 2033. Radiopharmaceuticals are medications that include radioactive versions of chemical elements known as radioisotopes. Depending on the type of radiation they emit, radioisotopes can be used to diagnose or treat a variety of medical diseases. Their uses range from examining and treating various organs, including the brain, heart, kidney, and bone, to the treatment of cancer and hyperthyroidism. Radiopharmaceuticals are administered to patients via injection or orally, and they may be monitored and analyzed using external medical equipment and testing. Most nations have specialized safety measures in place to safeguard patients and health workers from the potential harmful effects of these pharmaceuticals.
Radiopharmaceuticals Market - IMG1
The radiopharmaceuticals market is primarily driven by the increase in prevalence of chronic diseases, rise in technological advancements, and growth in applications in diagnostic and therapeutic procedures. As the prevalence of chronic diseases such as cancer, cardiovascular disorders, and neurological conditions continues to rise, there is a growing demand for effective diagnostic tools and targeted treatments. Radiopharmaceuticals, with their ability to provide precise imaging and therapeutic options, are increasingly recognized as valuable tools in the fight against these diseases. In addition, advancements in imaging techniques such as PET and SPECT have significantly improved the accuracy and efficiency of diagnosis, enabling early detection and better management of diseases propels the market growth. Additionally, the emergence of personalized medicine approaches has fueled the demand for radiopharmaceuticals, as they allow for tailored treatments on the basis of individual patient characteristics and molecular targets. However, the high cost associated with the development and production of radiopharmaceuticals can be prohibitive, thus hindering the market growth. This includes expenses related to research, clinical trials, and manufacturing processes, and regulatory compliance. The complex nature of radiopharmaceuticals also requires specialized infrastructure and expertise, further adding to the financial burden. In contrast, ongoing R&D activities for radiopharmaceuticals are increasingly being explored for use in areas such as theranostics, which involves combining diagnostic imaging with targeted therapy that provides lucrative opportunities for the market growth. The radiopharmaceuticals market is segmented on the basis of type, application, radioisotope, end user, and region. On the basis of type, the market is bifurcated into diagnostic, and therapeutic. On the basis of application, the market is classified into cancer, cardiology and others. The cancer segment is further classified into prostate cancer, breast cancer, gastrointestinal cancer, lung cancer, brain tumors, and others. The others segment further bifurcated into Neurological Applications and other applications. On the basis of radioisotope, the market is classified into Iodine I, Gallium 68, Technetium 99m, Fluorine 18, Copper 64, Strontium 89, Yttrium 90, Radium 223, Actinium 225, Lutetium 177, Copper 67, Terbium 161, Zirconium 89, and others. On the basis of end user, the market is categorized into hospitals and clinics, medical imaging centers, and others. On the basis of region, the market is studied across North America (U.S. and Canada), Europe (Germany, UK, France, Spain, Italy, and Rest of Europe), Asia-Pacific (India, China, Australia, Japan, South Korea, Thailand, Malaysia, Indonesia, Singapore, Taiwan, Province Of China, and Rest of Asia-Pacific), and LAMEA (Brazil and Rest of LAMEA). Major key players that operate in the global radiopharmaceuticals market are Bayer AG, Cardinal Health, Eli Lilly and Company, Bracco, Isotopia Molecular Imaging Ltd., Actinium Pharmaceuticals, Inc., Novartis AG, Curium Pharma, Nihon Medi-Physics Co. Ltd., Jubilant Pharmova Limited, Eckert & Ziegler, NorthStar Radioisotopes, The State Atomic Energy Corporation ROSATOM, SOFIE, Lantheus, Telix Pharmaceuticals Limited, Clarity Pharmaceuticals, Fusion Pharmaceuticals Inc., PRECIRIX, ITM Isotope Technologies Munich SE, GE Healthcare, South African Nuclear Energy Corporation (Necsa), and Eczacibasi. Key players operating in the market have adopted agreement, acquisition, expansion, clinical trial, product approval, product upgrade, contract, product development, collaboration, geographical expansion, joint venture, and expansion, as their key strategies to expand their product portfolio.

Key Benefits for Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the radiopharmaceuticals market analysis from 2023 to 2033 to identify the prevailing radiopharmaceuticals market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the radiopharmaceuticals market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global radiopharmaceuticals market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers.Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)
  • Patient/epidemiology data at country, region, global level
  • Regulatory Guidelines
  • Additional company profiles with specific to client's interest
  • Additional country or region analysis- market size and forecast
  • Expanded list for Company Profiles
  • Historic market data
  • SWOT Analysis

Key Market Segments

By End User

  • Hospitals and Clinics
  • Medical Imaging Centers
  • Others

By Radioisotope

  • Technetium 99m
  • Gallium 68
  • Iodine I
  • Fluorine 18
  • Copper 64
  • Strontium 89
  • Yttrium 90
  • Radium 223
  • Actinium 225
  • Lutetium 177
  • Copper 67
  • Terbium 161
  • Zirconium 89
  • Others

By Application

  • Cancer
    • Type
    • Prostate Cancer
    • Breast Cancer
    • Gastrointestinal Cancer
    • Lung Cancer
    • Brain Tumors
    • Others
  • Cardiology
  • Others
    • Type
    • Neurological Applications
    • Other Applications

By Type

  • Diagnostic
  • Therapeutic

By Region

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
    • Malaysia
    • Indonesia
    • Singapore
    • Taiwan, Province Of China
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Rest of LAMEA

Key Market Players:

    • Cardinal Health
    • Eli Lilly and Company
    • Novartis AG
    • Jubilant Pharmova Limited
    • The State Atomic Energy Corporation ROSATOM
    • SOFIE
    • Telix Pharmaceuticals Limited
    • Clarity Pharmaceuticals
    • PRECIRIX
    • NorthStar Medical Radioisotopes
    • South African Nuclear Energy Corporation (Necsa)
    • Bayer AG
    • Bracco
    • Curium Pharma
    • Eckert & Ziegler
    • Lantheus
    • Nihon Medi-Physics Co. Ltd
    • Isotopia Molecular Imaging
    • ITM Isotope Technologies Munich SE
    • GE Healthcare
    • Actinium Pharmaceuticals, Inc.
    • Fusion Pharmaceuticals Inc.
    • Eczacibasi

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key market segments
  • 1.3. Key benefits to the stakeholders
  • 1.4. Research methodology
    • 1.4.1. Primary research
    • 1.4.2. Secondary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key findings
    • 3.2.1. Top impacting factors
    • 3.2.2. Top investment pockets
  • 3.3. Porter's five forces analysis
    • 3.3.1. Moderate bargaining power of suppliers
    • 3.3.2. Moderate low threat of new entrants
    • 3.3.3. Moderate threat of substitutes
    • 3.3.4. High intensity of rivalry
    • 3.3.5. Moderate bargaining power of buyers
  • 3.4. Market dynamics
    • 3.4.1. Drivers
      • 3.4.1.1. Increase in prevalence of chronic diseases
      • 3.4.1.2. Rise in adoption of strategies by key players
      • 3.4.1.3. Rise in R&D activities
    • 3.4.2. Restraints
      • 3.4.2.1. High cost of development and implementation of radiopharmaceuticals
    • 3.4.3. Opportunities
      • 3.4.3.1. Rise in number of pipeline products

CHAPTER 4: RADIOPHARMACEUTICALS MARKET, BY END USER

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. Hospitals and Clinics
    • 4.2.1. Key market trends, growth factors and opportunities
    • 4.2.2. Market size and forecast, by region
    • 4.2.3. Market share analysis by country
  • 4.3. Medical Imaging Centers
    • 4.3.1. Key market trends, growth factors and opportunities
    • 4.3.2. Market size and forecast, by region
    • 4.3.3. Market share analysis by country
  • 4.4. Others
    • 4.4.1. Key market trends, growth factors and opportunities
    • 4.4.2. Market size and forecast, by region
    • 4.4.3. Market share analysis by country

CHAPTER 5: RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE

  • 5.1. Overview
    • 5.1.1. Market size and forecast
  • 5.2. Technetium 99m
    • 5.2.1. Key market trends, growth factors and opportunities
    • 5.2.2. Market size and forecast, by region
    • 5.2.3. Market share analysis by country
  • 5.3. Gallium 68
    • 5.3.1. Key market trends, growth factors and opportunities
    • 5.3.2. Market size and forecast, by region
    • 5.3.3. Market share analysis by country
  • 5.4. Iodine I
    • 5.4.1. Key market trends, growth factors and opportunities
    • 5.4.2. Market size and forecast, by region
    • 5.4.3. Market share analysis by country
  • 5.5. Fluorine 18
    • 5.5.1. Key market trends, growth factors and opportunities
    • 5.5.2. Market size and forecast, by region
    • 5.5.3. Market share analysis by country
  • 5.6. Copper 64
    • 5.6.1. Key market trends, growth factors and opportunities
    • 5.6.2. Market size and forecast, by region
    • 5.6.3. Market share analysis by country
  • 5.7. Strontium 89
    • 5.7.1. Key market trends, growth factors and opportunities
    • 5.7.2. Market size and forecast, by region
    • 5.7.3. Market share analysis by country
  • 5.8. Yttrium 90
    • 5.8.1. Key market trends, growth factors and opportunities
    • 5.8.2. Market size and forecast, by region
    • 5.8.3. Market share analysis by country
  • 5.9. Radium 223
    • 5.9.1. Key market trends, growth factors and opportunities
    • 5.9.2. Market size and forecast, by region
    • 5.9.3. Market share analysis by country
  • 5.10. Actinium 225
    • 5.10.1. Key market trends, growth factors and opportunities
    • 5.10.2. Market size and forecast, by region
    • 5.10.3. Market share analysis by country
  • 5.11. Lutetium 177
    • 5.11.1. Key market trends, growth factors and opportunities
    • 5.11.2. Market size and forecast, by region
    • 5.11.3. Market share analysis by country
  • 5.12. Copper 67
    • 5.12.1. Key market trends, growth factors and opportunities
    • 5.12.2. Market size and forecast, by region
    • 5.12.3. Market share analysis by country
  • 5.13. Terbium 161
    • 5.13.1. Key market trends, growth factors and opportunities
    • 5.13.2. Market size and forecast, by region
    • 5.13.3. Market share analysis by country
  • 5.14. Zirconium 89
    • 5.14.1. Key market trends, growth factors and opportunities
    • 5.14.2. Market size and forecast, by region
    • 5.14.3. Market share analysis by country
  • 5.15. Others
    • 5.15.1. Key market trends, growth factors and opportunities
    • 5.15.2. Market size and forecast, by region
    • 5.15.3. Market share analysis by country

CHAPTER 6: RADIOPHARMACEUTICALS MARKET, BY APPLICATION

  • 6.1. Overview
    • 6.1.1. Market size and forecast
  • 6.2. Cancer
    • 6.2.1. Key market trends, growth factors and opportunities
    • 6.2.2. Market size and forecast, by region
    • 6.2.3. Market share analysis by country
    • 6.2.4. Cancer Radiopharmaceuticals Market by Type
  • 6.3. Cardiology
    • 6.3.1. Key market trends, growth factors and opportunities
    • 6.3.2. Market size and forecast, by region
    • 6.3.3. Market share analysis by country
  • 6.4. Others
    • 6.4.1. Key market trends, growth factors and opportunities
    • 6.4.2. Market size and forecast, by region
    • 6.4.3. Market share analysis by country
    • 6.4.4. Others Radiopharmaceuticals Market by Type

CHAPTER 7: RADIOPHARMACEUTICALS MARKET, BY TYPE

  • 7.1. Overview
    • 7.1.1. Market size and forecast
  • 7.2. Diagnostic
    • 7.2.1. Key market trends, growth factors and opportunities
    • 7.2.2. Market size and forecast, by region
    • 7.2.3. Market share analysis by country
  • 7.3. Therapeutic
    • 7.3.1. Key market trends, growth factors and opportunities
    • 7.3.2. Market size and forecast, by region
    • 7.3.3. Market share analysis by country

CHAPTER 8: RADIOPHARMACEUTICALS MARKET, BY REGION

  • 8.1. Overview
    • 8.1.1. Market size and forecast By Region
  • 8.2. North America
    • 8.2.1. Key market trends, growth factors and opportunities
    • 8.2.2. Market size and forecast, by End User
    • 8.2.3. Market size and forecast, by Radioisotope
    • 8.2.4. Market size and forecast, by Application
    • 8.2.5. Market size and forecast, by Type
    • 8.2.6. Market size and forecast, by country
      • 8.2.6.1. U.S.
      • 8.2.6.1.1. Market size and forecast, by End User
      • 8.2.6.1.2. Market size and forecast, by Radioisotope
      • 8.2.6.1.3. Market size and forecast, by Application
      • 8.2.6.1.4. Market size and forecast, by Type
      • 8.2.6.2. Canada
      • 8.2.6.2.1. Market size and forecast, by End User
      • 8.2.6.2.2. Market size and forecast, by Radioisotope
      • 8.2.6.2.3. Market size and forecast, by Application
      • 8.2.6.2.4. Market size and forecast, by Type
  • 8.3. Europe
    • 8.3.1. Key market trends, growth factors and opportunities
    • 8.3.2. Market size and forecast, by End User
    • 8.3.3. Market size and forecast, by Radioisotope
    • 8.3.4. Market size and forecast, by Application
    • 8.3.5. Market size and forecast, by Type
    • 8.3.6. Market size and forecast, by country
      • 8.3.6.1. Germany
      • 8.3.6.1.1. Market size and forecast, by End User
      • 8.3.6.1.2. Market size and forecast, by Radioisotope
      • 8.3.6.1.3. Market size and forecast, by Application
      • 8.3.6.1.4. Market size and forecast, by Type
      • 8.3.6.2. France
      • 8.3.6.2.1. Market size and forecast, by End User
      • 8.3.6.2.2. Market size and forecast, by Radioisotope
      • 8.3.6.2.3. Market size and forecast, by Application
      • 8.3.6.2.4. Market size and forecast, by Type
      • 8.3.6.3. UK
      • 8.3.6.3.1. Market size and forecast, by End User
      • 8.3.6.3.2. Market size and forecast, by Radioisotope
      • 8.3.6.3.3. Market size and forecast, by Application
      • 8.3.6.3.4. Market size and forecast, by Type
      • 8.3.6.4. Italy
      • 8.3.6.4.1. Market size and forecast, by End User
      • 8.3.6.4.2. Market size and forecast, by Radioisotope
      • 8.3.6.4.3. Market size and forecast, by Application
      • 8.3.6.4.4. Market size and forecast, by Type
      • 8.3.6.5. Spain
      • 8.3.6.5.1. Market size and forecast, by End User
      • 8.3.6.5.2. Market size and forecast, by Radioisotope
      • 8.3.6.5.3. Market size and forecast, by Application
      • 8.3.6.5.4. Market size and forecast, by Type
      • 8.3.6.6. Rest of Europe
      • 8.3.6.6.1. Market size and forecast, by End User
      • 8.3.6.6.2. Market size and forecast, by Radioisotope
      • 8.3.6.6.3. Market size and forecast, by Application
      • 8.3.6.6.4. Market size and forecast, by Type
  • 8.4. Asia-Pacific
    • 8.4.1. Key market trends, growth factors and opportunities
    • 8.4.2. Market size and forecast, by End User
    • 8.4.3. Market size and forecast, by Radioisotope
    • 8.4.4. Market size and forecast, by Application
    • 8.4.5. Market size and forecast, by Type
    • 8.4.6. Market size and forecast, by country
      • 8.4.6.1. Japan
      • 8.4.6.1.1. Market size and forecast, by End User
      • 8.4.6.1.2. Market size and forecast, by Radioisotope
      • 8.4.6.1.3. Market size and forecast, by Application
      • 8.4.6.1.4. Market size and forecast, by Type
      • 8.4.6.2. China
      • 8.4.6.2.1. Market size and forecast, by End User
      • 8.4.6.2.2. Market size and forecast, by Radioisotope
      • 8.4.6.2.3. Market size and forecast, by Application
      • 8.4.6.2.4. Market size and forecast, by Type
      • 8.4.6.3. India
      • 8.4.6.3.1. Market size and forecast, by End User
      • 8.4.6.3.2. Market size and forecast, by Radioisotope
      • 8.4.6.3.3. Market size and forecast, by Application
      • 8.4.6.3.4. Market size and forecast, by Type
      • 8.4.6.4. Australia
      • 8.4.6.4.1. Market size and forecast, by End User
      • 8.4.6.4.2. Market size and forecast, by Radioisotope
      • 8.4.6.4.3. Market size and forecast, by Application
      • 8.4.6.4.4. Market size and forecast, by Type
      • 8.4.6.5. South Korea
      • 8.4.6.5.1. Market size and forecast, by End User
      • 8.4.6.5.2. Market size and forecast, by Radioisotope
      • 8.4.6.5.3. Market size and forecast, by Application
      • 8.4.6.5.4. Market size and forecast, by Type
      • 8.4.6.6. Thailand
      • 8.4.6.6.1. Market size and forecast, by End User
      • 8.4.6.6.2. Market size and forecast, by Radioisotope
      • 8.4.6.6.3. Market size and forecast, by Application
      • 8.4.6.6.4. Market size and forecast, by Type
      • 8.4.6.7. Malaysia
      • 8.4.6.7.1. Market size and forecast, by End User
      • 8.4.6.7.2. Market size and forecast, by Radioisotope
      • 8.4.6.7.3. Market size and forecast, by Application
      • 8.4.6.7.4. Market size and forecast, by Type
      • 8.4.6.8. Indonesia
      • 8.4.6.8.1. Market size and forecast, by End User
      • 8.4.6.8.2. Market size and forecast, by Radioisotope
      • 8.4.6.8.3. Market size and forecast, by Application
      • 8.4.6.8.4. Market size and forecast, by Type
      • 8.4.6.9. Singapore
      • 8.4.6.9.1. Market size and forecast, by End User
      • 8.4.6.9.2. Market size and forecast, by Radioisotope
      • 8.4.6.9.3. Market size and forecast, by Application
      • 8.4.6.9.4. Market size and forecast, by Type
      • 8.4.6.10. Taiwan, Province Of China
      • 8.4.6.10.1. Market size and forecast, by End User
      • 8.4.6.10.2. Market size and forecast, by Radioisotope
      • 8.4.6.10.3. Market size and forecast, by Application
      • 8.4.6.10.4. Market size and forecast, by Type
      • 8.4.6.11. Rest of Asia-Pacific
      • 8.4.6.11.1. Market size and forecast, by End User
      • 8.4.6.11.2. Market size and forecast, by Radioisotope
      • 8.4.6.11.3. Market size and forecast, by Application
      • 8.4.6.11.4. Market size and forecast, by Type
  • 8.5. LAMEA
    • 8.5.1. Key market trends, growth factors and opportunities
    • 8.5.2. Market size and forecast, by End User
    • 8.5.3. Market size and forecast, by Radioisotope
    • 8.5.4. Market size and forecast, by Application
    • 8.5.5. Market size and forecast, by Type
    • 8.5.6. Market size and forecast, by country
      • 8.5.6.1. Brazil
      • 8.5.6.1.1. Market size and forecast, by End User
      • 8.5.6.1.2. Market size and forecast, by Radioisotope
      • 8.5.6.1.3. Market size and forecast, by Application
      • 8.5.6.1.4. Market size and forecast, by Type
      • 8.5.6.2. Rest of LAMEA
      • 8.5.6.2.1. Market size and forecast, by End User
      • 8.5.6.2.2. Market size and forecast, by Radioisotope
      • 8.5.6.2.3. Market size and forecast, by Application
      • 8.5.6.2.4. Market size and forecast, by Type

CHAPTER 9: COMPETITIVE LANDSCAPE

  • 9.1. Introduction
  • 9.2. Top winning strategies
  • 9.3. Product mapping of top 10 player
  • 9.4. Competitive dashboard
  • 9.5. Competitive heatmap
  • 9.6. Top player positioning, 2023

CHAPTER 10: COMPANY PROFILES

  • 10.1. Bayer AG
    • 10.1.1. Company overview
    • 10.1.2. Key executives
    • 10.1.3. Company snapshot
    • 10.1.4. Operating business segments
    • 10.1.5. Product portfolio
    • 10.1.6. Business performance
    • 10.1.7. Key strategic moves and developments
  • 10.2. Cardinal Health
    • 10.2.1. Company overview
    • 10.2.2. Key executives
    • 10.2.3. Company snapshot
    • 10.2.4. Operating business segments
    • 10.2.5. Product portfolio
    • 10.2.6. Business performance
    • 10.2.7. Key strategic moves and developments
  • 10.3. Curium Pharma
    • 10.3.1. Company overview
    • 10.3.2. Key executives
    • 10.3.3. Company snapshot
    • 10.3.4. Operating business segments
    • 10.3.5. Product portfolio
    • 10.3.6. Key strategic moves and developments
  • 10.4. Eli Lilly and Company
    • 10.4.1. Company overview
    • 10.4.2. Key executives
    • 10.4.3. Company snapshot
    • 10.4.4. Operating business segments
    • 10.4.5. Product portfolio
    • 10.4.6. Business performance
    • 10.4.7. Key strategic moves and developments
  • 10.5. Jubilant Pharmova Limited
    • 10.5.1. Company overview
    • 10.5.2. Key executives
    • 10.5.3. Company snapshot
    • 10.5.4. Operating business segments
    • 10.5.5. Product portfolio
    • 10.5.6. Business performance
    • 10.5.7. Key strategic moves and developments
  • 10.6. Lantheus
    • 10.6.1. Company overview
    • 10.6.2. Key executives
    • 10.6.3. Company snapshot
    • 10.6.4. Operating business segments
    • 10.6.5. Product portfolio
    • 10.6.6. Business performance
    • 10.6.7. Key strategic moves and developments
  • 10.7. ITM Isotope Technologies Munich SE
    • 10.7.1. Company overview
    • 10.7.2. Key executives
    • 10.7.3. Company snapshot
    • 10.7.4. Operating business segments
    • 10.7.5. Product portfolio
    • 10.7.6. Key strategic moves and developments
  • 10.8. Telix Pharmaceuticals Limited
    • 10.8.1. Company overview
    • 10.8.2. Key executives
    • 10.8.3. Company snapshot
    • 10.8.4. Operating business segments
    • 10.8.5. Product portfolio
    • 10.8.6. Business performance
    • 10.8.7. Key strategic moves and developments
  • 10.9. Eckert & Ziegler
    • 10.9.1. Company overview
    • 10.9.2. Key executives
    • 10.9.3. Company snapshot
    • 10.9.4. Operating business segments
    • 10.9.5. Product portfolio
    • 10.9.6. Business performance
    • 10.9.7. Key strategic moves and developments
  • 10.10. Bracco
    • 10.10.1. Company overview
    • 10.10.2. Key executives
    • 10.10.3. Company snapshot
    • 10.10.4. Operating business segments
    • 10.10.5. Product portfolio
    • 10.10.6. Key strategic moves and developments
  • 10.11. South African Nuclear Energy Corporation (NECSA)
    • 10.11.1. Company overview
    • 10.11.2. Key executives
    • 10.11.3. Company snapshot
    • 10.11.4. Operating business segments
    • 10.11.5. Product portfolio
    • 10.11.6. Business performance
    • 10.11.7. Key strategic moves and developments
  • 10.12. NorthStar Medical Radioisotopes
    • 10.12.1. Company overview
    • 10.12.2. Key executives
    • 10.12.3. Company snapshot
    • 10.12.4. Operating business segments
    • 10.12.5. Product portfolio
    • 10.12.6. Key strategic moves and developments
  • 10.13. The State Atomic Energy Corporation ROSATOM
    • 10.13.1. Company overview
    • 10.13.2. Key executives
    • 10.13.3. Company snapshot
    • 10.13.4. Operating business segments
    • 10.13.5. Product portfolio
    • 10.13.6. Key strategic moves and developments
  • 10.14. SOFIE
    • 10.14.1. Company overview
    • 10.14.2. Key executives
    • 10.14.3. Company snapshot
    • 10.14.4. Operating business segments
    • 10.14.5. Product portfolio
    • 10.14.6. Key strategic moves and developments
  • 10.15. Isotopia Molecular Imaging
    • 10.15.1. Company overview
    • 10.15.2. Key executives
    • 10.15.3. Company snapshot
    • 10.15.4. Operating business segments
    • 10.15.5. Product portfolio
    • 10.15.6. Key strategic moves and developments
  • 10.16. Fusion Pharmaceuticals Inc.
    • 10.16.1. Company overview
    • 10.16.2. Key executives
    • 10.16.3. Company snapshot
    • 10.16.4. Operating business segments
    • 10.16.5. Product portfolio
    • 10.16.6. Key strategic moves and developments
  • 10.17. Clarity Pharmaceuticals
    • 10.17.1. Company overview
    • 10.17.2. Key executives
    • 10.17.3. Company snapshot
    • 10.17.4. Operating business segments
    • 10.17.5. Product portfolio
    • 10.17.6. Key strategic moves and developments
  • 10.18. Actinium Pharmaceuticals, Inc.
    • 10.18.1. Company overview
    • 10.18.2. Key executives
    • 10.18.3. Company snapshot
    • 10.18.4. Operating business segments
    • 10.18.5. Product portfolio
    • 10.18.6. Business performance
    • 10.18.7. Key strategic moves and developments
  • 10.19. PRECIRIX
    • 10.19.1. Company overview
    • 10.19.2. Key executives
    • 10.19.3. Company snapshot
    • 10.19.4. Operating business segments
    • 10.19.5. Product portfolio
    • 10.19.6. Key strategic moves and developments
  • 10.20. Novartis AG
    • 10.20.1. Company overview
    • 10.20.2. Key executives
    • 10.20.3. Company snapshot
    • 10.20.4. Operating business segments
    • 10.20.5. Product portfolio
    • 10.20.6. Business performance
    • 10.20.7. Key strategic moves and developments
  • 10.21. Nihon Medi-Physics Co. Ltd
    • 10.21.1. Company overview
    • 10.21.2. Key executives
    • 10.21.3. Company snapshot
    • 10.21.4. Operating business segments
    • 10.21.5. Product portfolio
  • 10.22. GE Healthcare
    • 10.22.1. Company overview
    • 10.22.2. Key executives
    • 10.22.3. Company snapshot
    • 10.22.4. Operating business segments
    • 10.22.5. Product portfolio
    • 10.22.6. Business performance
    • 10.22.7. Key strategic moves and developments
  • 10.23. Eczacibasi
    • 10.23.1. Company overview
    • 10.23.2. Key executives
    • 10.23.3. Company snapshot
    • 10.23.4. Operating business segments
    • 10.23.5. Product portfolio
    • 10.23.6. Business performance
    • 10.23.7. Key strategic moves and developments

LIST OF TABLES

  • TABLE 01. GLOBAL RADIOPHARMACEUTICALS MARKET, BY END USER, 2023-2033 ($MILLION)
  • TABLE 02. RADIOPHARMACEUTICALS MARKET FOR HOSPITALS AND CLINICS, BY REGION, 2023-2033 ($MILLION)
  • TABLE 03. RADIOPHARMACEUTICALS MARKET FOR MEDICAL IMAGING CENTERS, BY REGION, 2023-2033 ($MILLION)
  • TABLE 04. RADIOPHARMACEUTICALS MARKET FOR OTHERS, BY REGION, 2023-2033 ($MILLION)
  • TABLE 05. GLOBAL RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE, 2023-2033 ($MILLION)
  • TABLE 06. RADIOPHARMACEUTICALS MARKET FOR TECHNETIUM 99M, BY REGION, 2023-2033 ($MILLION)
  • TABLE 07. RADIOPHARMACEUTICALS MARKET FOR GALLIUM 68, BY REGION, 2023-2033 ($MILLION)
  • TABLE 08. RADIOPHARMACEUTICALS MARKET FOR IODINE I, BY REGION, 2023-2033 ($MILLION)
  • TABLE 09. RADIOPHARMACEUTICALS MARKET FOR FLUORINE 18, BY REGION, 2023-2033 ($MILLION)
  • TABLE 10. RADIOPHARMACEUTICALS MARKET FOR COPPER 64, BY REGION, 2023-2033 ($MILLION)
  • TABLE 11. RADIOPHARMACEUTICALS MARKET FOR STRONTIUM 89, BY REGION, 2023-2033 ($MILLION)
  • TABLE 12. RADIOPHARMACEUTICALS MARKET FOR YTTRIUM 90, BY REGION, 2023-2033 ($MILLION)
  • TABLE 13. RADIOPHARMACEUTICALS MARKET FOR RADIUM 223, BY REGION, 2023-2033 ($MILLION)
  • TABLE 14. RADIOPHARMACEUTICALS MARKET FOR ACTINIUM 225, BY REGION, 2023-2033 ($MILLION)
  • TABLE 15. RADIOPHARMACEUTICALS MARKET FOR LUTETIUM 177, BY REGION, 2023-2033 ($MILLION)
  • TABLE 16. RADIOPHARMACEUTICALS MARKET FOR COPPER 67, BY REGION, 2023-2033 ($MILLION)
  • TABLE 17. RADIOPHARMACEUTICALS MARKET FOR TERBIUM 161, BY REGION, 2023-2033 ($MILLION)
  • TABLE 18. RADIOPHARMACEUTICALS MARKET FOR ZIRCONIUM 89, BY REGION, 2023-2033 ($MILLION)
  • TABLE 19. RADIOPHARMACEUTICALS MARKET FOR OTHERS, BY REGION, 2023-2033 ($MILLION)
  • TABLE 20. GLOBAL RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2023-2033 ($MILLION)
  • TABLE 21. RADIOPHARMACEUTICALS MARKET FOR CANCER, BY REGION, 2023-2033 ($MILLION)
  • TABLE 22. GLOBAL CANCER RADIOPHARMACEUTICALS MARKET, BY TYPE, 2023-2033 ($MILLION)
  • TABLE 23. RADIOPHARMACEUTICALS MARKET FOR CARDIOLOGY, BY REGION, 2023-2033 ($MILLION)
  • TABLE 24. RADIOPHARMACEUTICALS MARKET FOR OTHERS, BY REGION, 2023-2033 ($MILLION)
  • TABLE 25. GLOBAL OTHERS RADIOPHARMACEUTICALS MARKET, BY TYPE, 2023-2033 ($MILLION)
  • TABLE 26. GLOBAL RADIOPHARMACEUTICALS MARKET, BY TYPE, 2023-2033 ($MILLION)
  • TABLE 27. RADIOPHARMACEUTICALS MARKET FOR DIAGNOSTIC, BY REGION, 2023-2033 ($MILLION)
  • TABLE 28. RADIOPHARMACEUTICALS MARKET FOR THERAPEUTIC, BY REGION, 2023-2033 ($MILLION)
  • TABLE 29. RADIOPHARMACEUTICALS MARKET, BY REGION, 2023-2033 ($MILLION)
  • TABLE 30. NORTH AMERICA RADIOPHARMACEUTICALS MARKET, BY END USER, 2023-2033 ($MILLION)
  • TABLE 31. NORTH AMERICA RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE, 2023-2033 ($MILLION)
  • TABLE 32. NORTH AMERICA RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2023-2033 ($MILLION)
  • TABLE 33. NORTH AMERICA RADIOPHARMACEUTICALS MARKET, BY TYPE, 2023-2033 ($MILLION)
  • TABLE 34. NORTH AMERICA RADIOPHARMACEUTICALS MARKET, BY COUNTRY, 2023-2033 ($MILLION)
  • TABLE 35. U.S. RADIOPHARMACEUTICALS MARKET, BY END USER, 2023-2033 ($MILLION)
  • TABLE 36. U.S. RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE, 2023-2033 ($MILLION)
  • TABLE 37. U.S. RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2023-2033 ($MILLION)
  • TABLE 38. U.S. RADIOPHARMACEUTICALS MARKET, BY TYPE, 2023-2033 ($MILLION)
  • TABLE 39. CANADA RADIOPHARMACEUTICALS MARKET, BY END USER, 2023-2033 ($MILLION)
  • TABLE 40. CANADA RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE, 2023-2033 ($MILLION)
  • TABLE 41. CANADA RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2023-2033 ($MILLION)
  • TABLE 42. CANADA RADIOPHARMACEUTICALS MARKET, BY TYPE, 2023-2033 ($MILLION)
  • TABLE 43. EUROPE RADIOPHARMACEUTICALS MARKET, BY END USER, 2023-2033 ($MILLION)
  • TABLE 44. EUROPE RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE, 2023-2033 ($MILLION)
  • TABLE 45. EUROPE RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2023-2033 ($MILLION)
  • TABLE 46. EUROPE RADIOPHARMACEUTICALS MARKET, BY TYPE, 2023-2033 ($MILLION)
  • TABLE 47. EUROPE RADIOPHARMACEUTICALS MARKET, BY COUNTRY, 2023-2033 ($MILLION)
  • TABLE 48. GERMANY RADIOPHARMACEUTICALS MARKET, BY END USER, 2023-2033 ($MILLION)
  • TABLE 49. GERMANY RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE, 2023-2033 ($MILLION)
  • TABLE 50. GERMANY RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2023-2033 ($MILLION)
  • TABLE 51. GERMANY RADIOPHARMACEUTICALS MARKET, BY TYPE, 2023-2033 ($MILLION)
  • TABLE 52. FRANCE RADIOPHARMACEUTICALS MARKET, BY END USER, 2023-2033 ($MILLION)
  • TABLE 53. FRANCE RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE, 2023-2033 ($MILLION)
  • TABLE 54. FRANCE RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2023-2033 ($MILLION)
  • TABLE 55. FRANCE RADIOPHARMACEUTICALS MARKET, BY TYPE, 2023-2033 ($MILLION)
  • TABLE 56. UK RADIOPHARMACEUTICALS MARKET, BY END USER, 2023-2033 ($MILLION)
  • TABLE 57. UK RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE, 2023-2033 ($MILLION)
  • TABLE 58. UK RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2023-2033 ($MILLION)
  • TABLE 59. UK RADIOPHARMACEUTICALS MARKET, BY TYPE, 2023-2033 ($MILLION)
  • TABLE 60. ITALY RADIOPHARMACEUTICALS MARKET, BY END USER, 2023-2033 ($MILLION)
  • TABLE 61. ITALY RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE, 2023-2033 ($MILLION)
  • TABLE 62. ITALY RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2023-2033 ($MILLION)
  • TABLE 63. ITALY RADIOPHARMACEUTICALS MARKET, BY TYPE, 2023-2033 ($MILLION)
  • TABLE 64. SPAIN RADIOPHARMACEUTICALS MARKET, BY END USER, 2023-2033 ($MILLION)
  • TABLE 65. SPAIN RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE, 2023-2033 ($MILLION)
  • TABLE 66. SPAIN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2023-2033 ($MILLION)
  • TABLE 67. SPAIN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2023-2033 ($MILLION)
  • TABLE 68. REST OF EUROPE RADIOPHARMACEUTICALS MARKET, BY END USER, 2023-2033 ($MILLION)
  • TABLE 69. REST OF EUROPE RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE, 2023-2033 ($MILLION)
  • TABLE 70. REST OF EUROPE RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2023-2033 ($MILLION)
  • TABLE 71. REST OF EUROPE RADIOPHARMACEUTICALS MARKET, BY TYPE, 2023-2033 ($MILLION)
  • TABLE 72. ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET, BY END USER, 2023-2033 ($MILLION)
  • TABLE 73. ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE, 2023-2033 ($MILLION)
  • TABLE 74. ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2023-2033 ($MILLION)
  • TABLE 75. ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET, BY TYPE, 2023-2033 ($MILLION)
  • TABLE 76. ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET, BY COUNTRY, 2023-2033 ($MILLION)
  • TABLE 77. JAPAN RADIOPHARMACEUTICALS MARKET, BY END USER, 2023-2033 ($MILLION)
  • TABLE 78. JAPAN RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE, 2023-2033 ($MILLION)
  • TABLE 79. JAPAN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2023-2033 ($MILLION)
  • TABLE 80. JAPAN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2023-2033 ($MILLION)
  • TABLE 81. CHINA RADIOPHARMACEUTICALS MARKET, BY END USER, 2023-2033 ($MILLION)
  • TABLE 82. CHINA RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE, 2023-2033 ($MILLION)
  • TABLE 83. CHINA RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2023-2033 ($MILLION)
  • TABLE 84. CHINA RADIOPHARMACEUTICALS MARKET, BY TYPE, 2023-2033 ($MILLION)
  • TABLE 85. INDIA RADIOPHARMACEUTICALS MARKET, BY END USER, 2023-2033 ($MILLION)
  • TABLE 86. INDIA RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE, 2023-2033 ($MILLION)
  • TABLE 87. INDIA RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2023-2033 ($MILLION)
  • TABLE 88. INDIA RADIOPHARMACEUTICALS MARKET, BY TYPE, 2023-2033 ($MILLION)
  • TABLE 89. AUSTRALIA RADIOPHARMACEUTICALS MARKET, BY END USER, 2023-2033 ($MILLION)
  • TABLE 90. AUSTRALIA RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE, 2023-2033 ($MILLION)
  • TABLE 91. AUSTRALIA RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2023-2033 ($MILLION)
  • TABLE 92. AUSTRALIA RADIOPHARMACEUTICALS MARKET, BY TYPE, 2023-2033 ($MILLION)
  • TABLE 93. SOUTH KOREA RADIOPHARMACEUTICALS MARKET, BY END USER, 2023-2033 ($MILLION)
  • TABLE 94. SOUTH KOREA RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE, 2023-2033 ($MILLION)
  • TABLE 95. SOUTH KOREA RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2023-2033 ($MILLION)
  • TABLE 96. SOUTH KOREA RADIOPHARMACEUTICALS MARKET, BY TYPE, 2023-2033 ($MILLION)
  • TABLE 97. THAILAND RADIOPHARMACEUTICALS MARKET, BY END USER, 2023-2033 ($MILLION)
  • TABLE 98. THAILAND RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE, 2023-2033 ($MILLION)
  • TABLE 99. THAILAND RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2023-2033 ($MILLION)
  • TABLE 100. THAILAND RADIOPHARMACEUTICALS MARKET, BY TYPE, 2023-2033 ($MILLION)
  • TABLE 101. MALAYSIA RADIOPHARMACEUTICALS MARKET, BY END USER, 2023-2033 ($MILLION)
  • TABLE 102. MALAYSIA RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE, 2023-2033 ($MILLION)
  • TABLE 103. MALAYSIA RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2023-2033 ($MILLION)
  • TABLE 104. MALAYSIA RADIOPHARMACEUTICALS MARKET, BY TYPE, 2023-2033 ($MILLION)
  • TABLE 105. INDONESIA RADIOPHARMACEUTICALS MARKET, BY END USER, 2023-2033 ($MILLION)
  • TABLE 106. INDONESIA RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE, 2023-2033 ($MILLION)
  • TABLE 107. INDONESIA RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2023-2033 ($MILLION)
  • TABLE 108. INDONESIA RADIOPHARMACEUTICALS MARKET, BY TYPE, 2023-2033 ($MILLION)
  • TABLE 109. SINGAPORE RADIOPHARMACEUTICALS MARKET, BY END USER, 2023-2033 ($MILLION)
  • TABLE 110. SINGAPORE RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE, 2023-2033 ($MILLION)
  • TABLE 111. SINGAPORE RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2023-2033 ($MILLION)
  • TABLE 112. SINGAPORE RADIOPHARMACEUTICALS MARKET, BY TYPE, 2023-2033 ($MILLION)
  • TABLE 113. TAIWAN, PROVINCE OF CHINA RADIOPHARMACEUTICALS MARKET, BY END USER, 2023-2033 ($MILLION)
  • TABLE 114. TAIWAN, PROVINCE OF CHINA RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE, 2023-2033 ($MILLION)
  • TABLE 115. TAIWAN, PROVINCE OF CHINA RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2023-2033 ($MILLION)
  • TABLE 116. TAIWAN, PROVINCE OF CHINA RADIOPHARMACEUTICALS MARKET, BY TYPE, 2023-2033 ($MILLION)
  • TABLE 117. REST OF ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET, BY END USER, 2023-2033 ($MILLION)
  • TABLE 118. REST OF ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE, 2023-2033 ($MILLION)
  • TABLE 119. REST OF ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2023-2033 ($MILLION)
  • TABLE 120. REST OF ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET, BY TYPE, 2023-2033 ($MILLION)
  • TABLE 121. LAMEA RADIOPHARMACEUTICALS MARKET, BY END USER, 2023-2033 ($MILLION)
  • TABLE 122. LAMEA RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE, 2023-2033 ($MILLION)
  • TABLE 123. LAMEA RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2023-2033 ($MILLION)
  • TABLE 124. LAMEA RADIOPHARMACEUTICALS MARKET, BY TYPE, 2023-2033 ($MILLION)
  • TABLE 125. LAMEA RADIOPHARMACEUTICALS MARKET, BY COUNTRY, 2023-2033 ($MILLION)
  • TABLE 126. BRAZIL RADIOPHARMACEUTICALS MARKET, BY END USER, 2023-2033 ($MILLION)
  • TABLE 127. BRAZIL RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE, 2023-2033 ($MILLION)
  • TABLE 128. BRAZIL RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2023-2033 ($MILLION)
  • TABLE 129. BRAZIL RADIOPHARMACEUTICALS MARKET, BY TYPE, 2023-2033 ($MILLION)
  • TABLE 130. REST OF LAMEA RADIOPHARMACEUTICALS MARKET, BY END USER, 2023-2033 ($MILLION)
  • TABLE 131. REST OF LAMEA RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE, 2023-2033 ($MILLION)
  • TABLE 132. REST OF LAMEA RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2023-2033 ($MILLION)
  • TABLE 133. REST OF LAMEA RADIOPHARMACEUTICALS MARKET, BY TYPE, 2023-2033 ($MILLION)
  • TABLE 134. BAYER AG: KEY EXECUTIVES
  • TABLE 135. BAYER AG: COMPANY SNAPSHOT
  • TABLE 136. BAYER AG: PRODUCT SEGMENTS
  • TABLE 137. BAYER AG: PRODUCT PORTFOLIO
  • TABLE 138. BAYER AG: KEY STRATEGIES
  • TABLE 139. CARDINAL HEALTH: KEY EXECUTIVES
  • TABLE 140. CARDINAL HEALTH: COMPANY SNAPSHOT
  • TABLE 141. CARDINAL HEALTH: PRODUCT SEGMENTS
  • TABLE 142. CARDINAL HEALTH: PRODUCT PORTFOLIO
  • TABLE 143. CARDINAL HEALTH: KEY STRATEGIES
  • TABLE 144. CURIUM PHARMA: KEY EXECUTIVES
  • TABLE 145. CURIUM PHARMA: COMPANY SNAPSHOT
  • TABLE 146. CURIUM PHARMA: PRODUCT SEGMENTS
  • TABLE 147. CURIUM PHARMA: PRODUCT PORTFOLIO
  • TABLE 148. CURIUM PHARMA: KEY STRATEGIES
  • TABLE 149. ELI LILLY AND COMPANY: KEY EXECUTIVES
  • TABLE 150. ELI LILLY AND COMPANY: COMPANY SNAPSHOT
  • TABLE 151. ELI LILLY AND COMPANY: PRODUCT SEGMENTS
  • TABLE 152. ELI LILLY AND COMPANY: PRODUCT PORTFOLIO
  • TABLE 153. ELI LILLY AND COMPANY: KEY STRATEGIES
  • TABLE 154. JUBILANT PHARMOVA LIMITED: KEY EXECUTIVES
  • TABLE 155. JUBILANT PHARMOVA LIMITED: COMPANY SNAPSHOT
  • TABLE 156. JUBILANT PHARMOVA LIMITED: PRODUCT SEGMENTS
  • TABLE 157. JUBILANT PHARMOVA LIMITED: PRODUCT PORTFOLIO
  • TABLE 158. JUBILANT PHARMOVA LIMITED: KEY STRATEGIES
  • TABLE 159. LANTHEUS: KEY EXECUTIVES
  • TABLE 160. LANTHEUS: COMPANY SNAPSHOT
  • TABLE 161. LANTHEUS: PRODUCT SEGMENTS
  • TABLE 162. LANTHEUS: PRODUCT PORTFOLIO
  • TABLE 163. LANTHEUS: KEY STRATEGIES
  • TABLE 164. ITM ISOTOPE TECHNOLOGIES MUNICH SE: KEY EXECUTIVES
  • TABLE 165. ITM ISOTOPE TECHNOLOGIES MUNICH SE: COMPANY SNAPSHOT
  • TABLE 166. ITM ISOTOPE TECHNOLOGIES MUNICH SE: PRODUCT SEGMENTS
  • TABLE 167. ITM ISOTOPE TECHNOLOGIES MUNICH SE: PRODUCT PORTFOLIO
  • TABLE 168. ITM ISOTOPE TECHNOLOGIES MUNICH SE: KEY STRATEGIES
  • TABLE 169. TELIX PHARMACEUTICALS LIMITED: KEY EXECUTIVES
  • TABLE 170. TELIX PHARMACEUTICALS LIMITED: COMPANY SNAPSHOT
  • TABLE 171. TELIX PHARMACEUTICALS LIMITED: PRODUCT SEGMENTS
  • TABLE 172. TELIX PHARMACEUTICALS LIMITED: PRODUCT PORTFOLIO
  • TABLE 173. TELIX PHARMACEUTICALS LIMITED: KEY STRATEGIES
  • TABLE 174. ECKERT & ZIEGLER: KEY EXECUTIVES
  • TABLE 175. ECKERT & ZIEGLER: COMPANY SNAPSHOT
  • TABLE 176. ECKERT & ZIEGLER: PRODUCT SEGMENTS
  • TABLE 177. ECKERT & ZIEGLER: PRODUCT PORTFOLIO
  • TABLE 178. ECKERT & ZIEGLER: KEY STRATEGIES
  • TABLE 179. BRACCO: KEY EXECUTIVES
  • TABLE 180. BRACCO: COMPANY SNAPSHOT
  • TABLE 181. BRACCO: PRODUCT SEGMENTS
  • TABLE 182. BRACCO: PRODUCT PORTFOLIO
  • TABLE 183. BRACCO: KEY STRATEGIES
  • TABLE 184. SOUTH AFRICAN NUCLEAR ENERGY CORPORATION (NECSA): KEY EXECUTIVES
  • TABLE 185. SOUTH AFRICAN NUCLEAR ENERGY CORPORATION (NECSA): COMPANY SNAPSHOT
  • TABLE 186. SOUTH AFRICAN NUCLEAR ENERGY CORPORATION (NECSA): PRODUCT SEGMENTS
  • TABLE 187. SOUTH AFRICAN NUCLEAR ENERGY CORPORATION (NECSA): PRODUCT PORTFOLIO
  • TABLE 188. SOUTH AFRICAN NUCLEAR ENERGY CORPORATION (NECSA): KEY STRATEGIES
  • TABLE 189. NORTHSTAR MEDICAL RADIOISOTOPES: KEY EXECUTIVES
  • TABLE 190. NORTHSTAR MEDICAL RADIOISOTOPES: COMPANY SNAPSHOT
  • TABLE 191. NORTHSTAR MEDICAL RADIOISOTOPES: PRODUCT SEGMENTS
  • TABLE 192. NORTHSTAR MEDICAL RADIOISOTOPES: PRODUCT PORTFOLIO
  • TABLE 193. NORTHSTAR MEDICAL RADIOISOTOPES: KEY STRATEGIES
  • TABLE 194. THE STATE ATOMIC ENERGY CORPORATION ROSATOM: KEY EXECUTIVES
  • TABLE 195. THE STATE ATOMIC ENERGY CORPORATION ROSATOM: COMPANY SNAPSHOT
  • TABLE 196. THE STATE ATOMIC ENERGY CORPORATION ROSATOM: PRODUCT SEGMENTS
  • TABLE 197. THE STATE ATOMIC ENERGY CORPORATION ROSATOM: PRODUCT PORTFOLIO
  • TABLE 198. THE STATE ATOMIC ENERGY CORPORATION ROSATOM: KEY STRATEGIES
  • TABLE 199. SOFIE: KEY EXECUTIVES
  • TABLE 200. SOFIE: COMPANY SNAPSHOT
  • TABLE 201. SOFIE: PRODUCT SEGMENTS
  • TABLE 202. SOFIE: PRODUCT PORTFOLIO
  • TABLE 203. SOFIE: KEY STRATEGIES
  • TABLE 204. ISOTOPIA MOLECULAR IMAGING: KEY EXECUTIVES
  • TABLE 205. ISOTOPIA MOLECULAR IMAGING: COMPANY SNAPSHOT
  • TABLE 206. ISOTOPIA MOLECULAR IMAGING: PRODUCT SEGMENTS
  • TABLE 207. ISOTOPIA MOLECULAR IMAGING: PRODUCT PORTFOLIO
  • TABLE 208. ISOTOPIA MOLECULAR IMAGING: KEY STRATEGIES
  • TABLE 209. FUSION PHARMACEUTICALS INC.: KEY EXECUTIVES
  • TABLE 210. FUSION PHARMACEUTICALS INC.: COMPANY SNAPSHOT
  • TABLE 211. FUSION PHARMACEUTICALS INC.: PRODUCT SEGMENTS
  • TABLE 212. FUSION PHARMACEUTICALS INC.: PRODUCT PORTFOLIO
  • TABLE 213. FUSION PHARMACEUTICALS INC.: KEY STRATEGIES
  • TABLE 214. CLARITY PHARMACEUTICALS: KEY EXECUTIVES
  • TABLE 215. CLARITY PHARMACEUTICALS: COMPANY SNAPSHOT
  • TABLE 216. CLARITY PHARMACEUTICALS: PRODUCT SEGMENTS
  • TABLE 217. CLARITY PHARMACEUTICALS: PRODUCT PORTFOLIO
  • TABLE 218. CLARITY PHARMACEUTICALS: KEY STRATEGIES
  • TABLE 219. ACTINIUM PHARMACEUTICALS, INC.: KEY EXECUTIVES
  • TABLE 220. ACTINIUM PHARMACEUTICALS, INC.: COMPANY SNAPSHOT
  • TABLE 221. ACTINIUM PHARMACEUTICALS, INC.: PRODUCT SEGMENTS
  • TABLE 222. ACTINIUM PHARMACEUTICALS, INC.: PRODUCT PORTFOLIO
  • TABLE 223. ACTINIUM PHARMACEUTICALS, INC.: KEY STRATEGIES
  • TABLE 224. PRECIRIX: KEY EXECUTIVES
  • TABLE 225. PRECIRIX: COMPANY SNAPSHOT
  • TABLE 226. PRECIRIX: PRODUCT SEGMENTS
  • TABLE 227. PRECIRIX: PRODUCT PORTFOLIO
  • TABLE 228. PRECIRIX: KEY STRATEGIES
  • TABLE 229. NOVARTIS AG: KEY EXECUTIVES
  • TABLE 230. NOVARTIS AG: COMPANY SNAPSHOT
  • TABLE 231. NOVARTIS AG: PRODUCT SEGMENTS
  • TABLE 232. NOVARTIS AG: PRODUCT PORTFOLIO
  • TABLE 233. NOVARTIS AG: KEY STRATEGIES
  • TABLE 234. NIHON MEDI-PHYSICS CO. LTD: KEY EXECUTIVES
  • TABLE 235. NIHON MEDI-PHYSICS CO. LTD: COMPANY SNAPSHOT
  • TABLE 236. NIHON MEDI-PHYSICS CO. LTD: PRODUCT SEGMENTS
  • TABLE 237. NIHON MEDI-PHYSICS CO. LTD: PRODUCT PORTFOLIO
  • TABLE 238. GE HEALTHCARE: KEY EXECUTIVES
  • TABLE 239. GE HEALTHCARE: COMPANY SNAPSHOT
  • TABLE 240. GE HEALTHCARE: PRODUCT SEGMENTS
  • TABLE 241. GE HEALTHCARE: SERVICE SEGMENTS
  • TABLE 242. GE HEALTHCARE: PRODUCT PORTFOLIO
  • TABLE 243. GE HEALTHCARE: KEY STRATEGIES
  • TABLE 244. ECZACIBASI: KEY EXECUTIVES
  • TABLE 245. ECZACIBASI: COMPANY SNAPSHOT
  • TABLE 246. ECZACIBASI: PRODUCT SEGMENTS
  • TABLE 247. ECZACIBASI: PRODUCT PORTFOLIO
  • TABLE 248. ECZACIBASI: KEY STRATEGIES

LIST OF FIGURES

  • FIGURE 01. RADIOPHARMACEUTICALS MARKET, 2023-2033
  • FIGURE 02. SEGMENTATION OF RADIOPHARMACEUTICALS MARKET,2023-2033
  • FIGURE 03. TOP IMPACTING FACTORS IN RADIOPHARMACEUTICALS MARKET (2023 TO 2033)
  • FIGURE 04. TOP INVESTMENT POCKETS IN RADIOPHARMACEUTICALS MARKET (2024-2033)
  • FIGURE 05. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 06. MODERATE LOW THREAT OF NEW ENTRANTS
  • FIGURE 07. MODERATE THREAT OF SUBSTITUTES
  • FIGURE 08. HIGH INTENSITY OF RIVALRY
  • FIGURE 09. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 10. GLOBAL RADIOPHARMACEUTICALS MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
  • FIGURE 11. RADIOPHARMACEUTICALS MARKET, BY END USER, 2023 AND 2033(%)
  • FIGURE 12. COMPARATIVE SHARE ANALYSIS OF RADIOPHARMACEUTICALS MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY 2023 AND 2033(%)
  • FIGURE 13. COMPARATIVE SHARE ANALYSIS OF RADIOPHARMACEUTICALS MARKET FOR MEDICAL IMAGING CENTERS, BY COUNTRY 2023 AND 2033(%)
  • FIGURE 14. COMPARATIVE SHARE ANALYSIS OF RADIOPHARMACEUTICALS MARKET FOR OTHERS, BY COUNTRY 2023 AND 2033(%)
  • FIGURE 15. RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE, 2023 AND 2033(%)
  • FIGURE 16. COMPARATIVE SHARE ANALYSIS OF RADIOPHARMACEUTICALS MARKET FOR TECHNETIUM 99M, BY COUNTRY 2023 AND 2033(%)
  • FIGURE 17. COMPARATIVE SHARE ANALYSIS OF RADIOPHARMACEUTICALS MARKET FOR GALLIUM 68, BY COUNTRY 2023 AND 2033(%)
  • FIGURE 18. COMPARATIVE SHARE ANALYSIS OF RADIOPHARMACEUTICALS MARKET FOR IODINE I, BY COUNTRY 2023 AND 2033(%)
  • FIGURE 19. COMPARATIVE SHARE ANALYSIS OF RADIOPHARMACEUTICALS MARKET FOR FLUORINE 18, BY COUNTRY 2023 AND 2033(%)
  • FIGURE 20. COMPARATIVE SHARE ANALYSIS OF RADIOPHARMACEUTICALS MARKET FOR COPPER 64, BY COUNTRY 2023 AND 2033(%)
  • FIGURE 21. COMPARATIVE SHARE ANALYSIS OF RADIOPHARMACEUTICALS MARKET FOR STRONTIUM 89, BY COUNTRY 2023 AND 2033(%)
  • FIGURE 22. COMPARATIVE SHARE ANALYSIS OF RADIOPHARMACEUTICALS MARKET FOR YTTRIUM 90, BY COUNTRY 2023 AND 2033(%)
  • FIGURE 23. COMPARATIVE SHARE ANALYSIS OF RADIOPHARMACEUTICALS MARKET FOR RADIUM 223, BY COUNTRY 2023 AND 2033(%)
  • FIGURE 24. COMPARATIVE SHARE ANALYSIS OF RADIOPHARMACEUTICALS MARKET FOR ACTINIUM 225, BY COUNTRY 2023 AND 2033(%)
  • FIGURE 25. COMPARATIVE SHARE ANALYSIS OF RADIOPHARMACEUTICALS MARKET FOR LUTETIUM 177, BY COUNTRY 2023 AND 2033(%)
  • FIGURE 26. COMPARATIVE SHARE ANALYSIS OF RADIOPHARMACEUTICALS MARKET FOR COPPER 67, BY COUNTRY 2023 AND 2033(%)
  • FIGURE 27. COMPARATIVE SHARE ANALYSIS OF RADIOPHARMACEUTICALS MARKET FOR TERBIUM 161, BY COUNTRY 2023 AND 2033(%)
  • FIGURE 28. COMPARATIVE SHARE ANALYSIS OF RADIOPHARMACEUTICALS MARKET FOR ZIRCONIUM 89, BY COUNTRY 2023 AND 2033(%)
  • FIGURE 29. COMPARATIVE SHARE ANALYSIS OF RADIOPHARMACEUTICALS MARKET FOR OTHERS, BY COUNTRY 2023 AND 2033(%)
  • FIGURE 30. RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2023 AND 2033(%)
  • FIGURE 31. COMPARATIVE SHARE ANALYSIS OF RADIOPHARMACEUTICALS MARKET FOR CANCER, BY COUNTRY 2023 AND 2033(%)
  • FIGURE 32. COMPARATIVE SHARE ANALYSIS OF RADIOPHARMACEUTICALS MARKET FOR CARDIOLOGY, BY COUNTRY 2023 AND 2033(%)
  • FIGURE 33. COMPARATIVE SHARE ANALYSIS OF RADIOPHARMACEUTICALS MARKET FOR OTHERS, BY COUNTRY 2023 AND 2033(%)
  • FIGURE 34. RADIOPHARMACEUTICALS MARKET, BY TYPE, 2023 AND 2033(%)
  • FIGURE 35. COMPARATIVE SHARE ANALYSIS OF RADIOPHARMACEUTICALS MARKET FOR DIAGNOSTIC, BY COUNTRY 2023 AND 2033(%)
  • FIGURE 36. COMPARATIVE SHARE ANALYSIS OF RADIOPHARMACEUTICALS MARKET FOR THERAPEUTIC, BY COUNTRY 2023 AND 2033(%)
  • FIGURE 37. RADIOPHARMACEUTICALS MARKET BY REGION, 2023 AND 2033(%)
  • FIGURE 38. U.S. RADIOPHARMACEUTICALS MARKET, 2023-2033 ($MILLION)
  • FIGURE 39. CANADA RADIOPHARMACEUTICALS MARKET, 2023-2033 ($MILLION)
  • FIGURE 40. GERMANY RADIOPHARMACEUTICALS MARKET, 2023-2033 ($MILLION)
  • FIGURE 41. FRANCE RADIOPHARMACEUTICALS MARKET, 2023-2033 ($MILLION)
  • FIGURE 42. UK RADIOPHARMACEUTICALS MARKET, 2023-2033 ($MILLION)
  • FIGURE 43. ITALY RADIOPHARMACEUTICALS MARKET, 2023-2033 ($MILLION)
  • FIGURE 44. SPAIN RADIOPHARMACEUTICALS MARKET, 2023-2033 ($MILLION)
  • FIGURE 45. REST OF EUROPE RADIOPHARMACEUTICALS MARKET, 2023-2033 ($MILLION)
  • FIGURE 46. JAPAN RADIOPHARMACEUTICALS MARKET, 2023-2033 ($MILLION)
  • FIGURE 47. CHINA RADIOPHARMACEUTICALS MARKET, 2023-2033 ($MILLION)
  • FIGURE 48. INDIA RADIOPHARMACEUTICALS MARKET, 2023-2033 ($MILLION)
  • FIGURE 49. AUSTRALIA RADIOPHARMACEUTICALS MARKET, 2023-2033 ($MILLION)
  • FIGURE 50. SOUTH KOREA RADIOPHARMACEUTICALS MARKET, 2023-2033 ($MILLION)
  • FIGURE 51. THAILAND RADIOPHARMACEUTICALS MARKET, 2023-2033 ($MILLION)
  • FIGURE 52. MALAYSIA RADIOPHARMACEUTICALS MARKET, 2023-2033 ($MILLION)
  • FIGURE 53. INDONESIA RADIOPHARMACEUTICALS MARKET, 2023-2033 ($MILLION)
  • FIGURE 54. SINGAPORE RADIOPHARMACEUTICALS MARKET, 2023-2033 ($MILLION)
  • FIGURE 55. TAIWAN, PROVINCE OF CHINA RADIOPHARMACEUTICALS MARKET, 2023-2033 ($MILLION)
  • FIGURE 56. REST OF ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET, 2023-2033 ($MILLION)
  • FIGURE 57. BRAZIL RADIOPHARMACEUTICALS MARKET, 2023-2033 ($MILLION)
  • FIGURE 58. REST OF LAMEA RADIOPHARMACEUTICALS MARKET, 2023-2033 ($MILLION)
  • FIGURE 59. TOP WINNING STRATEGIES, BY YEAR (2021-2024)
  • FIGURE 60. TOP WINNING STRATEGIES, BY DEVELOPMENT (2021-2024)
  • FIGURE 61. TOP WINNING STRATEGIES, BY COMPANY (2021-2024)
  • FIGURE 62. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 63. COMPETITIVE DASHBOARD
  • FIGURE 64. COMPETITIVE HEATMAP: RADIOPHARMACEUTICALS MARKET
  • FIGURE 65. TOP PLAYER POSITIONING, 2023
  • FIGURE 66. BAYER AG: NET SALES, 2021-2023 ($MILLION)
  • FIGURE 67. BAYER AG: RESEARCH & DEVELOPMENT EXPENDITURE, 2021-2023 ($MILLION)
  • FIGURE 68. BAYER AG: REVENUE SHARE BY SEGMENT, 2023 (%)
  • FIGURE 69. BAYER AG: REVENUE SHARE BY REGION, 2023 (%)
  • FIGURE 70. CARDINAL HEALTH: NET REVENUE, 2021-2023 ($MILLION)
  • FIGURE 71. CARDINAL HEALTH: REVENUE SHARE BY SEGMENT, 2023 (%)
  • FIGURE 72. CARDINAL HEALTH: REVENUE SHARE BY REGION, 2023 (%)
  • FIGURE 73. ELI LILLY AND COMPANY: NET REVENUE, 2021-2023 ($MILLION)
  • FIGURE 74. ELI LILLY AND COMPANY: REVENUE SHARE BY REGION, 2023 (%)
  • FIGURE 75. JUBILANT PHARMOVA LIMITED: NET REVENUE, 2021-2023 ($MILLION)
  • FIGURE 76. JUBILANT PHARMOVA LIMITED: REVENUE SHARE BY SEGMENT, 2023 (%)
  • FIGURE 77. JUBILANT PHARMOVA LIMITED: REVENUE SHARE BY REGION, 2023 (%)
  • FIGURE 78. LANTHEUS: NET REVENUE, 2021-2023 ($MILLION)
  • FIGURE 79. LANTHEUS: REVENUE SHARE BY SEGMENT, 2023 (%)
  • FIGURE 80. TELIX PHARMACEUTICALS LIMITED: NET REVENUE, 2021-2023 ($MILLION)
  • FIGURE 81. TELIX PHARMACEUTICALS LIMITED: REVENUE SHARE BY REGION, 2023 (%)
  • FIGURE 82. ECKERT & ZIEGLER: NET SALES, 2021-2023 ($MILLION)
  • FIGURE 83. ECKERT & ZIEGLER: REVENUE SHARE BY SEGMENT, 2023 (%)
  • FIGURE 84. ECKERT & ZIEGLER: REVENUE SHARE BY REGION, 2023 (%)
  • FIGURE 85. SOUTH AFRICAN NUCLEAR ENERGY CORPORATION (NECSA): NET REVENUE, 2021-2023 ($MILLION)
  • FIGURE 86. ACTINIUM PHARMACEUTICALS, INC.: NET REVENUE, 2021-2023 ($MILLION)
  • FIGURE 87. NOVARTIS AG: NET SALES, 2021-2023 ($MILLION)
  • FIGURE 88. NOVARTIS AG: REVENUE SHARE BY REGION, 2023 (%)
  • FIGURE 89. GE HEALTHCARE: NET REVENUE, 2021-2023 ($MILLION)
  • FIGURE 90. GE HEALTHCARE: REVENUE SHARE BY SEGMENT, 2023 (%)
  • FIGURE 91. GE HEALTHCARE: REVENUE SHARE BY REGION, 2023 (%)
  • FIGURE 92. ECZACIBASI: NET REVENUE, 2020-2022 ($MILLION)